Aldeyra Therapeutics, Inc. (ALDX)
| Market Cap | 72.69M -75.8% |
| Revenue (ttm) | n/a |
| Net Income | -23.05M |
| EPS | -0.38 |
| Shares Out | 60.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,707 |
| Open | 1.230 |
| Previous Close | 1.220 |
| Day's Range | 1.195 - 1.280 |
| 52-Week Range | 1.070 - 5.930 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | 6.60 (+447.72%) |
| Est. Earnings | Nov 4, 2026 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ALDX stock is "Buy." The 12-month stock price target is $6.6, which is an increase of 447.72% from the latest price.
News
Aldeyra Therapeutics Quarterly report: Q2 2026
Aldeyra Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Levicept Appoints Darlene Deptula-Hicks as CFO
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens ...
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a late-stage dry eye disease program facing regulatory hurdles, with a pivotal FDA meeting and possible appeal ahead. Strong cash reserves, a robust pipeline, and a partnership with AbbVie position it for multiple near-term catalysts and long-term growth.
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims
A class action lawsuit was filed against Aldeyra Therapeutics ($ALDX) on March 30, 2026. Plaintiffs in the federal securities lawsuit allege that they acquired Aldeyra stock at artificially inflated p...
Aldeyra Therapeutics Quarterly report: Q1 2026
Aldeyra Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role o...
Aldeyra Therapeutics Proxy statement: Proxy filing
Aldeyra Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Aldeyra Therapeutics Proxy statement: Proxy filing
Aldeyra Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email...
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (...
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from…
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus...
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug application, or NDA, of reproxalap, an investigational drug candidate, for the treatment…
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
Aldeyra Therapeutics stock fell hard on Tuesday after it received a CRL from the FDA.
US FDA declines to approve Aldeyra's drug for eye disorder
The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said.
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Annual report: Q4 2025
Aldeyra Therapeutics has published its Q4 2025 annual report on February 27, 2026.
Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Reproxalap is nearing a key FDA decision for dry eye disease, with potential to uniquely address both dry eye and allergic conjunctivitis. Strategic collaboration with AbbVie could bring significant financial milestones and commercial strength.
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Slides: Corporate Presentation
Aldeyra Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on December 16, 2025.
Aldeyra Therapeutics Transcript: Study Update
The FDA extended the PDUFA date for reproxalap's NDA after requesting a field trial CSR, despite prior agreement to omit it. The review is nearly complete, and labeling discussions are underway, with a decision expected by February 2026. The AbbVie partnership terms remain unchanged.
Aldeyra Therapeutics Press release: Study Update
Aldeyra Therapeutics issued a press release on December 16, 2025, disclosing material business information to investors.
Aldeyra announces PDUFA extension for Reproxalap
The company states: “Aldeyra (ALDX) Therapeutics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application for the…